Guardant Health, Inc.

for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star 1 on your telephone keypad. I would now like to pass the conference over to your host, Saret Khurshid, Vice President of Investor Relations. You may proceed.

Thank you. Earlier today, Garden Health released financial results for the quarter ended June 30th, 2024. Joining me today from Garden are Helmi Otuki, co-CEO, Amiralee Talasaz, co-CEO, and Mike Bell, Chief Financial Officer. Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to differ materially from those anticipated. This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items. Additional information regarding material risks and uncertainties, as well as reconciliation to most directly comparable GAAP financial measures, are available in the press release GARDEN issued today, as well as in our 10-K and other filings with the SEC. GARDEN disclaims any intention or obligation to update or revise financial projections and forward-looking statements, whether because of for new information, future events, or otherwise. The information in this conference call is accurate only as of the live broadcast. With that, I would like to turn the call over to Helmi.

Thanks, Eric. Good afternoon, and thank you for joining our second quarter 2024 earnings call. We founded Garden Health with a bold mission to conquer cancer with data. With our comprehensive suite of tests, we are now truly transforming patient lives across the continuum of care. It has always been our belief that the best way to conquer cancer is to catch it in its earliest stages when patients have the best chance of survival. We have spent the last decade developing a blood-based test that we believe will launch cancer screening into a whole new era with vastly improved screening rates, earlier cancer detection, and ultimately a significant increase in the number of lives saved. We have reached a pivotal moment on this journey, and to commemorate this important milestone, Amir Ali will start us off with an update on our screening business.